First regulatory approval for the first-of-its-kind, fully-integrated PFA system with a simple and reproducible workflow Integrated with the world's leading CARTO™ 3D cardiac mapping system for the ...
Johnson & Johnson Medtech’s Biosense Webster division presented the final results from a yearlong study of its upcoming Varipulse pulsed field ablation system, showing that more than three-quarters of ...
IRVINE, CA – October 14, 2020 – Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, ...
Findings from the admIRE study – freedom from atrial arrhythmia recurrence at 12 months – support the submission of the VARIPULSE™ Platform among U.S. patients IRVINE, Calif., March 25, 2024 ...
Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium
IRVINE, Calif., Feb. 2, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi, announced 12-month results from the company ...
Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow. Integrated with the world's leading CARTO™ 3D Cardiac Mapping System for the ...
IRVINE, Calif., Jan. 9, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, i today announced approval from the Japanese ...
Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, today announced European CE mark approval of the VARIPULSE™ Platform for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results